Related Experiment Videos
[Continuous arteriovenous hemofiltration in the newborn infant]
F Castillo Salinas1, J Nieto Rey, S Salcedo Abizanda
1Servicio de Neonatología, Hospital Universitario, Materno-Infantil Valle Hebrón, Barcelona.
Anales Espanoles De Pediatria
|May 20, 1999
Summary
Continuous arterio-venous hemofiltration (CAVH) effectively treats acute renal failure (ARF) in newborns. This study shows CAVH is a useful option for critically ill neonates with ARF.
Area of Science:
- Neonatal Medicine
- Pediatric Nephrology
- Critical Care
Context:
- Acute renal failure (ARF) is a critical condition in newborns.
- Neonates often present with complex etiologies requiring intensive management.
- Limited treatment options exist for neonatal ARF, necessitating innovative approaches.
Purpose:
- To evaluate the efficacy and safety of continuous arterio-venous hemofiltration (CAVH) in treating newborns with ARF.
- To assess the outcomes and complications associated with CAVH in a neonatal population.
- To determine the utility of CAVH as a therapeutic intervention for oligoanuric neonates.
Summary:
- Twelve newborns with ARF of various causes underwent CAVH using Gambro FH 22 or Amicon Minifilter.
- Treatment duration varied (8-120 hours) with a median ultrafiltration of 25 ml/h.
- CAVH was well-tolerated, with complications including hypotension and hypoglycemia; renal function normalized in 6 infants, while 6 died from cardiac malformation or multi-organ failure.
Impact:
- CAVH demonstrates utility in managing neonatal ARF, offering a potential life-saving intervention.
- The study highlights the feasibility of CAVH in a neonatal intensive care setting.
- Findings contribute to the understanding of extracorporeal therapies for pediatric critical illness.